Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine Plus Lutetium Lu 177 Dotatate vs Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
NCT05724108Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of triapine in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate up to 5 years. Started Aug 2023; status: active, not recruiting.
02
Drugs
triapine
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT05724108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724108.